

THE BRIDGE

FIRST EUROPEAN LUNG CANCER BOARD

CHAIRMAN

Diego Luigi Cortinovis
Medical Oncologist, San Gerardo Hospital, Monza - Italy

STEERING COMMITTEE

Vanesa Gregorc
MD Thoracic Oncology and Melanoma Area Coordinator, Oncology Department
IRCCS Scientific Institute Ospedale San Raffaele-University Hospital, Milan - Italy

Maria Rita Migliorino
MD Director, Oncological Pulmonary Unit, Department of Lung Diseases,
Flajani Pavilion San Camillo, High Specialization Hospital, Rome - Italy

Alessandro Morabito
Thoracic Medical Oncology, National Cancer Institute Naples - Italy

Luca Toschi
Medical Oncologist, Operational Unit of Oncology and Hematology
Humanitas Cancer Center, IRCCS, Milan - Italy

Jesus Corral Jaime
Medical Oncology Department
Hospital Universitario Virgen del Rocío, Seville - Spain

Nicolas Girard
Respiratory Medicine Service
Hôpital Louis Pradel, Hospices Civils de Lyon - France

Thomas Newsom-Davis
BSc FRCP PhD, Consultant Medical Oncologist
Chelsea & Westminster Hospital, London - UK

Christian Rolfo
MD, PhD, MBAh Head of Phase I - Early Clinical Trials Unit Director of Clinical Trial Management
Program Oncology Department University Hospital Antwerp - Belgium

With the unrestricted grant of:



Scientific and Organizational Secretariat

Medica
EDITORIA E
DIFFUSIONE
SCIENTIFICA
Medica Editoria e Diffusione Scientifica srl
Corso Venezia, 37 - 20121 Milano
Tel. +39 02 76281337 - Fax 02 93661995
E-mail: info@medicacom.it

THE BRIDGE

FIRST EUROPEAN LUNG CANCER BOARD

November 18th 2016
Milan, Hotel Michelangelo Conference Center

Medica
EDITORIA E
DIFFUSIONE
SCIENTIFICA
Scientific and Organizational Secretariat

THE BRIDGE

FIRST EUROPEAN LUNG CANCER BOARD

SCIENTIFIC RATIONALE

Many efforts are done during last years taking care of lung cancer and several advances are reached in order to improve disease control. The knowledge of tumoral biology lead to some astonishing results in really focused disease subgroup. However, a gap between clinical research and clinical practice is sometimes even more evident with different availability and accessibility of newer drugs among european countries leading to different therapeutic algorithm applied in clinical practice beyond International guidelines.

The aim of this first European board is sharing experience among experts in lung cancer focused European physicians. The participants are invited, through a simple questions, to debate main important issues in lung cancer research in order to simplify, if possible, and make more close the scientific knowledge to clinical practice taking into account the different Countries that every physician represents.

At the end of the meeting the board will illustrate the brainstorming activity in a paper that will be proposed to a peer review journal.

AGENDA

- 10.00 – 10.10 Welcome and introduction
- 10.10 – 10.30 Rationale meeting exposure

SCIENTIFIC SESSION

- 10.30 – 10.50 Defecting lung cancer: what is the practical role of lung cancer prevention in your Country?
- 10.50 – 11.10 What is your perspective about adjuvant strategy in lung cancer today? Do you believe in actual chemotherapy indication and its clinical applicability?
- 11.10 – 11.30 What are your insights about the management of locally advanced NSCLC?
- 11.30 – 11.50 *Coffee Break*
- 11.50 – 12.10 The first line treatment in non oncogene addicted tumors: European experience comparison
- 12.10 – 12.30 The first line treatment in EGFR mut/ALK +ve advanced NSCLC: European experience comparison
- 12.30 – 13.30 *Lunch Buffet*
- 13.30 – 13.50 Evolving second line therapy: the role of immunotherapy
- 13.50 – 14.10 An antiangiogenic continuum: back to reality
- 14.10 – 14.30 Do all patients receive the best strategy? European perspective
- 14.30 – 14.50 The role of biomarkers and liquid biopsies in lung cancer: are we ready to start?
- 14.50 – 15.10 Which is the role of clinical research today?
- 15.10 – 15.30 *Coffee Break*
- 15.30 – 16.30 The “big Pharma universe” meets oncologists: sharing the pipeline and future strategy in clinical research. BI, BMS, Novartis intervene separately
- 16.30 – 17.00 Closing remarks and regards